211 reports of this reaction
1.4% of all ENTECAVIR reports
#18 most reported adverse reaction
HEPATOCELLULAR CARCINOMA is the #18 most commonly reported adverse reaction for ENTECAVIR, manufactured by E.R. Squibb & Sons, L.L.C.. There are 211 FDA adverse event reports linking ENTECAVIR to HEPATOCELLULAR CARCINOMA. This represents approximately 1.4% of all 15,216 adverse event reports for this drug.
Patients taking ENTECAVIR who experience hepatocellular carcinoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATOCELLULAR CARCINOMA is a less commonly reported adverse event for ENTECAVIR, but still significant enough to appear in the safety profile.
In addition to hepatocellular carcinoma, the following adverse reactions have been reported for ENTECAVIR:
The following drugs have also been linked to hepatocellular carcinoma in FDA adverse event reports:
HEPATOCELLULAR CARCINOMA has been reported as an adverse event in 211 FDA reports for ENTECAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATOCELLULAR CARCINOMA accounts for approximately 1.4% of all adverse event reports for ENTECAVIR, making it a notable side effect.
If you experience hepatocellular carcinoma while taking ENTECAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.